By Ben Glickman

Bausch Health Cos. has received approval from the Food and Drug Administration for Cabtreo, its topical gel for acne.

The Laval, Quebec-based pharmaceutical company said the treatment, which combines clindamycin phosphate, adapalene and benzoyl peroxide, is expected to become available in the first quarter of 2024.

The approved new drug application allows for the use of Cabtreo in treating acne vulgaris in patients 12 years and older.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

October 20, 2023 17:50 ET (21:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Bausch Health Companies (TSX:BHC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more Bausch Health Companies Charts.
Bausch Health Companies (TSX:BHC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more Bausch Health Companies Charts.